ArticleInvestigative ophthalmology & visual science2011
Naloxone ameliorates retinal lesions in Ccl2/Cx3cr1 double-deficient mice via modulation of microglia.
Article in Investigative ophthalmology & visual science, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Correlation of Functional and Structural Outcomes with Serum Antibody Profiles in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial.Journal of clinical medicine · 2024Article
- Intercellular communication atlas reveals Oprm1 as a neuroprotective factor for retinal ganglion cells.Nature communications · 2024Article
- CCR1 mediates Müller cell activation and photoreceptor cell death in macular and retinal degeneration.eLife · 2023Article
- Serum Autoantibodies in Patients with Dry and Wet Age-Related Macular Degeneration.Journal of clinical medicine · 2023Article
- Naloxone Protects against Lipopolysaccharide-Induced Neuroinflammation and Microglial Activation via Inhibiting ATP-Sensitive Potassium Channel.Computational and mathematical methods in medicine · 2021Article
- Neuroprotective Peptides in Retinal Disease.Journal of clinical medicine · 2019Review
- Models of retinal diseases and their applicability in drug discovery.Expert opinion on drug discovery · 2018Review
- Cytokine profiles in the aqueous humor and serum of patients with dry and treated wet age-related macular degeneration.PloS one · 2018Article
- NLRP3 Upregulation in Retinal Pigment Epithelium in Age-Related Macular Degeneration.International journal of molecular sciences · 2016Article
- Wnt signaling in age-related macular degeneration: human macular tissue and mouse model.Journal of translational medicine · 2015Article
- Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4.CNS & neurological disorders drug targets · 2015Review
- Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2014Article
- Article
- Article
- Aging is not a disease: distinguishing age-related macular degeneration from aging.Progress in retinal and eye research · 2013Review
- Early degeneration of photoreceptor synapse in Ccl2/Cx3cr1-deficient mice on Crb1(rd8) background.Synapse (New York, N.Y.) · 2013Article
- Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.The Journal of nutrition · 2013Article
- Stage-dependent anti-allodynic effects of intrathecal Toll-like receptor 4 antagonists in a rat model of cancer induced bone pain.The journal of physiological sciences : JPS · 2013Article
- Robust spinal neuroinflammation mediates mechanical allodynia in Walker 256 induced bone cancer rats.Molecular brain · 2012Article
- Anti-inflammatory recombinant TSG-6 stabilizes the progression of focal retinal degeneration in a murine model.Journal of neuroinflammation · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeThe role of naloxone, an opioid receptor antagonist, on microglial inhibition and neuroprotective effects has been reported in lipopolysaccharide (LPS)-induced neurodegeneration and light-induced photoreceptor degeneration. The authors evaluated the effects of naloxone on Ccl2(-/-)/Cx3cr1(-/-) (DKO) mice, a murine model of age-related macular degeneration (AMD).
methodsTwo-month-old DKO and wild-type controls were given daily intraperitoneal injections of naloxone or PBS for 2 months. Animals were examined monthly by funduscopy. Ocular tissue was analyzed histologically and in retinal flat mount preparations. Ocular A2E was measured using HPLC. Quantitative RT-PCR analyzed TNF-α, IL-1β, IL-10 and TLR4 transcripts in the DKO eyes and LPS activated culture microglial cells. Serum nitrite was measured using Griess colorimetric reaction.
resultsNaloxone ameliorated the clinical progression and severity of retinal lesions in the DKO mice compared with those of untreated controls. Histopathology also showed less focal retinal degeneration in the treated DKO mice than in controls. The aggregation of microglia in the outer retina in DKO mice was significantly reduced in naloxone-treated animals compared with control untreated DKO. Ocular TNF-α, IL-1β, and TLR4 transcripts and A2E were significantly lower in naloxone-treated DKO animals and cultured microglial cells than in controls, as were serum nitrite levels.
conclusionsNaloxone significantly reduces the progress of retinal lesions in DKO mice. Naloxone modulates microglia accumulation and activation at the site of retinal degeneration, which may be mediated by inhibition of the proinflammatory molecules of NO, TNF-α, and IL-β. The potential therapeutic effects of naloxone on retinal degeneration, including AMD, warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.